MedTrace Logo

A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

NCT03564145 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 547

Last updated 2021-12-15

Study results available
· View outcomes & findings →

Summary

To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).

Conditions

  • Papulopustular Rosacea

Interventions

DRUG

S5G4T-1

Once a day topical cream

Sponsors & Collaborators

  • Sol-Gel Technologies, Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-12
Primary Completion
2019-11-13
Completion
2019-11-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03564145 on ClinicalTrials.gov